Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 2;62(11):3757-3762.
doi: 10.1093/rheumatology/kead203.

Association of anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis

Rie Karasawa  1 , Kazuo Yudoh  1 , Toshiko Sato  1 , Megumi Tanaka  1 , Sara E Sabbagh  2   3 , Willy A Flegel  4 , Andrew L Mammen  2 , James N Jarvis  5   6 , Lisa G Rider  7 ; Childhood Myositis Heterogeneity Study Group
Collaborators, Affiliations

Association of anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis

Rie Karasawa et al. Rheumatology (Oxford). .

Abstract

Objectives: AECAs are detected in multiple forms of vasculitis or vasculopathy, including JDM. High levels of tropomyosin alpha-4 chain (TPM4) gene expression in cutaneous lesions and TPM4 protein expression in some endothelial cells (ECs) have been proven. Furthermore, the presence of autoantibodies to tropomyosin proteins have been discovered in DM. We therefore investigated whether anti-TPM4 autoantibodies are an AECA in JDM and are correlated with clinical features of JDM.

Methods: The expression of TPM4 protein in cultured normal human dermal microvascular ECs was investigated by Western blotting. Plasma samples from 63 children with JDM, 50 children with polyarticular JIA (pJIA) and 40 healthy children (HC) were tested for the presence of anti-TPM4 autoantibodies using an ELISA. Clinical features were compared between JDM patients with and without anti-TPM4 autoantibodies.

Results: Autoantibodies to TPM4 were detected in the plasma of 30% of JDM, 2% of pJIA (P < 0.0001) and 0% of HC (P < 0.0001). In JDM, anti-TPM4 autoantibodies were associated with the presence of cutaneous ulcers (53%; P = 0.02), shawl sign rash (47%; P = 0.03), mucous membrane lesions (84%; P = 0.04) and subcutaneous edema (42%; P < 0.05). Anti-TPM4 autoantibodies significantly correlated with the use of intravenous steroids and IVIG therapy in JDM (both P = 0.01). The total number of medications received was higher in patients with anti-TPM4 autoantibodies (P = 0.02).

Conclusion: Anti-TPM4 autoantibodies are detected frequently in children with JDM and are novel myositis-associated autoantibodies. Their presence correlates with vasculopathic and other cutaneous manifestations of JDM that may be indicative of more refractory disease.

Keywords: JDM; anti-endothelial cell antibodies; cutaneous manifestations; myositis-associated autoantibodies; tropomyosin alpha-4 chain; vasculopathy.

PubMed Disclaimer

References

    1. Crowe WE, Bove KE, Levinson JE, Hilton PK.. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 1982;25:126–39. - PubMed
    1. Banker BQ, Victor M.. Dermatomyositis (systemic angiopathy) of childhood. Medicine 1966;45:261–89. - PubMed
    1. Gitiaux C, De Antonio M, Aouizerate J. et al. Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis. Rheumatology (Oxford) 2016;55:470–9. - PubMed
    1. Karasawa R, Tamaki M, Sato T. et al. Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. Rheumatology (Oxford) 2018;57:671–6. - PMC - PubMed
    1. Karasawa R, Yudoh K, Sato T. et al. Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis. Rheumatology (Oxford) 2022;61:2969–77. - PMC - PubMed

Publication types